✦ LIBER ✦

Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer

✍ Scribed by Jordi Codony-Servat, Xabier Garcia-Albeniz, Carles Pericay, Vicente Alonso, Pilar Escudero, Carlos Fernández-Martos, Rosa Gallego, Anna Martínez-Cardús, Eva Martinez-Balibrea, Joan Maurel

Book ID: 118821798
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 420 KB
Volume: 30
Category: Article
ISSN: 1357-0560
DOI: 10.1007/s12032-012-0428-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacogenetic Profiling for Cetuximab

Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal Cancer

✍ Graziano, F.; Ruzzo, A.; Loupakis, F.; Canestrari, E.; Santini, D.; Catalano, V. 📂 Article 📅 2008 🏛 American Society of Clinical Oncology 🌐 English ⚖ 127 KB

Prediction of irinotecan and 5-fluoroura

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer

✍ Glimelius, B; Garmo, H; Berglund, Å; Fredriksson, L A; Berglund, M; Kohnke, H; B 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 477 KB

6113 BRAF V600E mutation and Amphireguli

6113 BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients

✍ Cremolini, C.; Loupakis, F.; Perrone, G.; Ruzzo, A.; Rulli, E.; Bencardino, K.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Dose escalating study of cetuximab and 5

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

✍ Gunnar Folprecht,Susanne Hamann,Katharina Schütte,Tanja Trarbach… 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 460 KB

Results of a Phase II Trial of Cetuximab

Results of a Phase II Trial of Cetuximab plus Capecitabine/Irinotecan as First-Line Therapy for Patients with Advanced and/or Metastatic Colorectal Cancer

✍ Thomas Cartwright; Paul Kuefler; Allen Cohn; William Hyman; Maury Berger; Donald 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 144 KB

Quantitative Cell-Free DNA, KRAS, and BR

Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan

✍ Spindler, K.-L. G.; Pallisgaard, N.; Vogelius, I.; Jakobsen, A. 📂 Article 📅 2012 🏛 American Association for Cancer Research 🌐 English ⚖ 311 KB